Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol

Timothy E Albertson1 Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USA;2 Department of Medicine, Veterans Administration Northern California Health Care System, Mather, CA, USA;3 Department of Emergency Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USACorrespondence[email protected]

Richart Harper1 Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USA;2 Department of Medicine, Veterans Administration Northern California Health Care System, Mather, CA, USA

Susan Murin1 Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USA;2 Department of Medicine, Veterans Administration Northern California Health Care System, Mather, CA, USA

Christian Sandrock1 Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USA

Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date